2023
Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
Kappelman M, Long M, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Fehlmann T, Brensinger C, Haynes K, Nair V, Kaul A, Dobes A, Lewis J. Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib. Crohn's & Colitis 360 2023, 5: otad031. PMID: 37350775, PMCID: PMC10284045, DOI: 10.1093/crocol/otad031.Peer-Reviewed Original ResearchUlcerative colitisIBD PartnersSecondary outcomesPain interferenceAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsEffectiveness of vedolizumabNecrosis factor therapyCo-primary outcomesProspective cohort studyPatient-reported outcomesSocial role satisfactionSecondary nonresponseVedolizumab usersSecondary endpointsTreatment persistenceCohort studyFactor therapyTreatment initiationBiological therapyTreatment groupsPatientsLarger sample sizeTofacitinibVedolizumab
2021
Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression
Kotlyar AM, Mamillapalli R, Flores VA, Taylor HS. Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression. Molecular Human Reproduction 2021, 27: gaab016. PMID: 33693775, PMCID: PMC8454207, DOI: 10.1093/molehr/gaab016.Peer-Reviewed Original ResearchConceptsLesion regressionIshikawa cellsJAK/STATGrowth factor mRNA levelsEffects of tofacitinibTreatment of endometriosisHypoxia-inducible factor-1αVascular endothelial growth factor (VEGF) mRNA levelsFactor mRNA levelsWidespread clinical useWestern blot analysisVehicle treatmentOral gavageGynecologic conditionsC57BL/6 miceEutopic endometriumJanus kinase/signal transducerReproductive ageEndometriosisJAK inhibitorsKinase/signal transducerTofacitinibTherapeutic targetLesion growthClinical useTofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series
Muzumdar S, Leonardi C, Strober B. Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. Journal Of Psoriasis And Psoriatic Arthritis 2021, 6: 93-98. DOI: 10.1177/2475530321995516.Peer-Reviewed Original ResearchPalmoplantar psoriasisCase seriesEfficacy of tofacitinibRecalcitrant palmoplantar psoriasisSubtypes of psoriasisPsoriasis refractorySystemic therapyPatients' qualityNew medicationsEffective therapyPsoriasis phenotypesSpecific cytokinesPsoriasisTofacitinibTherapyTreatmentMedicationsPatientsCytokinesSubtypes
2020
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal Of The American Academy Of Dermatology 2020, 82: 1445-1486. PMID: 32119894, DOI: 10.1016/j.jaad.2020.02.044.Peer-Reviewed Original ResearchConceptsDermatology–National Psoriasis Foundation guidelinesManagement of psoriasisTreatment of psoriasisChronic inflammatory diseaseFumaric acid estersMultiple organ systemsJoint American AcademyNonbiologic medicationsNonbiologic therapiesInflammatory diseasesFoundation guidelinesNew therapiesAmerican AcademyOrgan systemsMedicationsPsoriasisTherapyTreatmentDiseaseGuidelinesTofacitinibAcitretinPatientsApremilastPrescribersTreatment of Multiorgan Sarcoidosis With Tofacitinib
Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology 2020, 2: 106-109. PMID: 31916703, PMCID: PMC7011417, DOI: 10.1002/acr2.11112.Peer-Reviewed Original ResearchMultiorgan sarcoidosisTumor necrosis factor α blockadeNecrosis factor α blockadeCutaneous sarcoidosis lesionsEfficacy of tofacitinibIdiopathic inflammatory disorderJanus kinase inhibitorRecalcitrant sarcoidosisΑ-blockadeClinical remissionSarcoidosis lesionsGranulomatous inflammationInflammatory disordersAvid lesionsLesional tissueSarcoidosisJanus kinase-signal transducerSingle patientJAK inhibitorsJAK inhibitionKinase-signal transducerTofacitinibKinase inhibitorsActivator of transcriptionInternal organs
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis
2017
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME ASSOCIATED EOSINOPHILIC MYOCARDITIS TREATED WITH TOFACITINIB AN ORAL JANUS (JAK) KINASE INHIBITOR
Azari B, Chowdhury M, Riello R, Sthalekar N, King B, Ahmad T. DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME ASSOCIATED EOSINOPHILIC MYOCARDITIS TREATED WITH TOFACITINIB AN ORAL JANUS (JAK) KINASE INHIBITOR. Journal Of The American College Of Cardiology 2017, 69: 2351. DOI: 10.1016/s0735-1097(17)35740-6.Peer-Reviewed Original Research
2013
Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley R, Krishnaswami S, Papp K. Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. CPT Pharmacometrics & Systems Pharmacology 2013, 2: 1-8. PMCID: PMC3674331, DOI: 10.1038/psp.2013.22.Peer-Reviewed Original ResearchBody weightPlacebo-controlled dose-ranging studyOral Janus kinase inhibitorPhase III clinical trialsPharmacokinetics of tofacitinibChronic plaque psoriasisDose-ranging studyPlaque psoriasis treatmentJanus kinase inhibitorNonlinear mixed-effects modelingTofacitinib 2Tofacitinib 5Confirmatory phase III clinical trialDose-response profilesPlaque psoriasisSystemic exposurePsoriasis treatmentSubgroup analysisMixed-effects modelingClinical trialsClinical dataTofacitinibPsoriasisKinase inhibitorsReduced efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply